1例人型支原体感染超早产儿的药学监护实践  

Pharmaceutical Care for an Extremely Preterm Infant with Mycoplasma Hominis Infection by Clinical Pharmacists

作　　者：刘云媛[1] 唐静宜[2] 唐秀能[1] Liu Yunyuan;Tang Jingyi;Tang Xiuneng(Maternity and Child Health Care of Guangxi Zhuang Autonomous Region,Nanning 530000,China;Wuhan No.1 Hospital,Wuhan 430022,China)

机构地区：[1]广西壮族自治区妇幼保健院,南宁530000 [2]武汉市第一医院,武汉430022

出　　处：《儿科药学杂志》2024年第8期21-24,共4页Journal of Pediatric Pharmacy

基　　金：广西壮族自治区卫生健康委科研课题,编号Z-A20230349。

摘　　要：目的:探讨超早产儿人型支原体感染的抗菌药物选择及药学监护。方法:临床药师参与1例人型支原体感染超早产儿的治疗过程,通过查阅大量文献,协助医师选择适宜患儿的抗菌药物,并给出用药监护方案。结果:患儿经抗人型支原体药物治疗后,枕部疖肿消退;经联合其他抗菌药物治疗,体温、感染指标逐渐降至正常,未观察到药物不良反应。结论:临床药师参与特殊患儿个体化给药方案的制定与实施,可保障药物治疗安全、有效。Objective:To probe into the selection of antibiotics and pharmaceutical care of Mycoplasma hominis infection in extremely preterm infants.Methods:The clinical pharmacists participated into the treatment process of an extremely preterm infant with M.hominis infection.By consulting a large number of literature,clinical pharmacists assisted the clinicians in selecting the appropriate antibiotics for the infant,and provided pharmaceutical care regimen.Results:After treatment with anti-M.hominis therapy,the occipital swelling subsided.Combined with other antibiotics for treatment,the clinical symptoms and laboratory indicators were improved,and no adverse drug reactions were observed.Conclusion:Clinical pharmacists participate into the formulation of individualized administration regimen for special children can ensure the safety and effectiveness of drug therapy.

关 键 词：人型支原体 超早产儿 抗菌药物 药学实践 

分 类 号：R722.6[医药卫生—儿科]